Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Sees Significant Decrease in Short Interest

Posted by Micah Haroldson on Mar 27th, 2026

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR – Get Free Report) was the target of a large decline in short interest in the month of March. As of March 13th, there was short interest totaling 622 shares, a decline of 43.3% from the February 26th total of 1,097 shares. Currently, 0.4% of the company’s shares are short sold. Based on an average trading volume of 1,322 shares, the short-interest ratio is currently 0.5 days.

Hedge Funds Weigh In On Amplify Weight Loss Drug & Treatment ETF

A hedge fund recently bought a new stake in Amplify Weight Loss Drug & Treatment ETF stock. Cravens & Co Advisors LLC purchased a new stake in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 15,023 shares of the company’s stock, valued at approximately $390,000. Cravens & Co Advisors LLC owned 10.02% of Amplify Weight Loss Drug & Treatment ETF as of its most recent SEC filing.

Amplify Weight Loss Drug & Treatment ETF Stock Performance

Amplify Weight Loss Drug & Treatment ETF stock remained flat at $23.67 during trading on Friday. 71 shares of the company traded hands, compared to its average volume of 2,674. Amplify Weight Loss Drug & Treatment ETF has a 12-month low of $18.56 and a 12-month high of $27.28. The company has a fifty day simple moving average of $25.52 and a 200 day simple moving average of $24.88. The stock has a market cap of $3.55 million, a PE ratio of 24.31 and a beta of 0.61.

Amplify Weight Loss Drug & Treatment ETF Announces Dividend

The company also recently disclosed an annual dividend, which was paid on Wednesday, December 31st. Stockholders of record on Tuesday, December 30th were paid a $0.4132 dividend. The ex-dividend date of this dividend was Tuesday, December 30th. This represents a dividend yield of 162.0%.

About Amplify Weight Loss Drug & Treatment ETF

(Get Free Report)

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.